For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.
For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...
While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...
On the back of several strong quarters and a year already chock-full of manufacturing accords, Korean CDMO Samsung Biologics ...